After years of meticulous research, advocacy, and considerable investment in the realm of psychedelic therapeutics, there's a growing anticipation that the FDA will sanction MDMA-assisted therapy by August or September of this year.
Interestingly, as the global community gears up for this groundbreaking approval, a region not typically associated with being at the forefront of such medical innovations is making strides to embrace these therapies — the Middle East.
Thanks to the United Arab Emirates (UAE) avant-garde approach to health policy and the diligent efforts of several U.S.-based psychedelic advocacy groups over the past 14 months, the UAE could become the second nation worldwide to approve FDA-endorsed psychedelic treatments.
The UAE has, in recent years, carved out a niche for itself as a trailblazer in health care, technological advancement, and economic policy, fostering a vision that prioritizes the "future of everything." Organizations like the Energia Foundation and Tabula Rasa Ventures, which introduced psychedelic education at the prestigious Davos forum in 2022, have been instrumental in enlightening both public and private sector leaders in the UAE. They've engaged with policymakers, sovereign wealth funds, and healthcare practitioners, sharing insights into the potential benefits of these cutting-edge treatments.
Marik Hazan, the Executive Director of the Energia Foundation, reflected on their initiatives, stating, "Our work here has shown us that the UAE is one of the most forward-thinking, scientifically rigorous, and ambitious countries on the planet. We're grateful to the Department of Health, SEHA, and many of the other incredible institutions that are supportive of the psychedelic education we're bringing to the region."
Psychedelic Pioneers in the Middle East
As the scope of psychedelic medicine expands globally, fostering connections between leading experts in the field — primarily based in the United States, Canada, and Europe — and key health policy stakeholders worldwide becomes essential.
The Dialogues in Mental Health conference, held in June 2023, marked a historic milestone in the Arabian Gulf by integrating psychedelic programming into its agenda for the first time. This pivotal event provided a unique opportunity for renowned specialists such as Rachel Yehuda and Jesse Gould to present their findings on the therapeutic potentials of psychedelics. Joseph El Khoury, the visionary behind Valence Clinic, emphasized the conference's role in pioneering discussions about psychedelic-assisted therapy in the Middle East, thus opening new frontiers in mental health discourse within the region.
Following this significant event, the Energia Foundation, which orchestrated the psychedelic sessions at the conference, initiated a collaborative relationship with the Abu Dhabi Department of Health. By January 2024, this partnership culminated in the co-hosting of the psychedelic segment at the Abu Dhabi Integrated Mental Health conference. This gathering was distinguished by the attendance of royalty, regulatory figures, and therapists from across the region. The conference featured illustrious speakers like Rick Doblin, Sherry Rais, and Maria Velkova, alongside Dr. Rasheed Al Hammadi, the Director of the Department of Health in Abu Dhabi. Their collective dialogue not only highlighted ongoing research and developments in the domain but also laid the groundwork for potential regulatory adaptations and the introduction of psychedelic therapies in the UAE.
Nahida Nayaz Ahmed, Chief Medical Officer at SEHA Mental Health and Well-Being Services, shared her enthusiasm: "We were excited to host so many experts from the emerging field of psychedelic-assisted therapy. There's still a lot of important research that needs to be done, but I'm hopeful that these medicines can expand the arsenal of tools we have to treat our most pressing mental health challenges"
Unpacking the Challenges of Psychedelic Expansion
As the potential for psychedelic medicine garners global attention, the interest from financial powerhouses is also sparking. A notable development came in early February when Mubadala, the sovereign wealth fund of Abu Dhabi, expressed keen interest in channeling investments towards biotech firms that are pioneering the development of psychedelic medicines.
This burgeoning enthusiasm worldwide for the sanctioning of psychedelic medicines brings to light a pivotal question: What hurdles will entities like Lykos Therapeutics, previously known as MAPS PBC, encounter during the commercialization phase?
Maria Velkova, Managing Partner at Tabula Rasa Ventures, underscored the complexity of the challenge, stating, "Broad patient access hinges on training thousands of therapists for this multifaceted intervention, adapting clinics for 5- to 6-hour dosing sessions and REMS implementation, requiring funding and systemic shifts in mental healthcare. Payers need to also establish new reimbursement models for these therapies."
As we stand on the cusp of potentially historic regulatory approval, the trajectory of the psychedelic therapy movement over the coming years, both in the United States and internationally, remains an open question. Yet, it is evident that interest is mounting from all quarters — regulators, researchers, healthcare professionals, investors, and, critically, the patients who stand to benefit. The global community watches with bated breath, eager for the resolutions to these pressing inquiries and the transformative possibilities that psychedelic therapies may herald.
Uncommon Knowledge
Newsweek is committed to challenging conventional wisdom and finding connections in the search for common ground.
Newsweek is committed to challenging conventional wisdom and finding connections in the search for common ground.
About the writer
To read how Newsweek uses AI as a newsroom tool, Click here.
